Our relationships with the retina community are paramount to the success of our business. The Eyetech Team is committed to be the most knowledgeable sales force in the ophthalmic industry. Below are a few examples of our commitment to help address the needs of the retina community:
Delivery of Macugen: The Luer Lok® Syringe
- Only FDA approved pre-filled syringe designed for intravitreal injection
- Improved detached 30-gauge needle for comfort and consistency
- Entire syringe package is terminally sterilized for delivery safety
- Entire syringe package is terminally sterilized for delivery safety
- Click here for Luer Lok® Instructions
Macugen Access Program™ (MAP)
Our enhanced Macugen Access Program assists patients with reimbursement. MAP has experienced counselors who will help answer your patients’ questions so your office staff does not have to spend time helping patients navigate the reimbursement process.
Click here to learn more about the MAP program.
Advancing the Future of Retina
Eyetech partners with retina specialists to fund independent research. For more information on how to submit a request, please contact nan.parker@eyetech.com.
Please refer to the links on the left for further information.
Contact Us
Email: nan.parker@eyetech.com
Phone: (919)325-2788
Fax: (866)744-6697
Address:
11360 Jog Road Ste 200
Palm Beach Gardens, FL 33418
Macugen® (pegaptanib sodium injection) is indicated for the treatment of neovascular age-related macular degeneration.
Important Safety Information
MACUGEN is contraindicated in patients with ocular or periocular infections or with known hypersensitivity to pegaptanib sodium or any other excipient in this product.
Safety or efficacy of MACUGEN beyond 2 years has not been demonstrated.
Intravitreal injections including those with MACUGEN have been associated with endophthalmitis. Proper aseptic injection technique—which includes use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent)—should always be utilized when administering MACUGEN. In addition, patients should be monitored during the week following the injection to permit early treatment, should an infection occur.
Increases in intraocular pressure (IOP) have been seen within 30 minutes of injection with MACUGEN. Therefore, IOP as well as the perfusion of the optic nerve head should be monitored and managed appropriately.
Rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been reported in postmarketing experience following the intravitreal administration procedure.
Serious adverse events related to the injection procedure occurring in <1% of intravitreal injections included endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.
Most frequently reported adverse events in patients treated for up to 2 years were anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased IOP, ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities. These events occurred in approximately 10% to 40% of patients.